利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

57 条记录 (耗时 0.043 秒)

    Acylated Spiropiperidine Derivatives as Melanocortin-4 Receptor Modulators
    51.
    发明申请
    Acylated Spiropiperidine Derivatives as Melanocortin-4 Receptor Modulators 有权
    酰基化Spiropiperidine衍生物作为黑皮质素-4受体调节剂

    公开(公告)号：US20090170863A1

    公开(公告)日：2009-07-02

    申请号：US11992262

    申请日：2006-09-25

    申请人： Tianying Jian ,  Jian Liu ,  Ravi P. Nargund

    发明人： Tianying Jian ,  Jian Liu ,  Ravi P. Nargund

    IPC分类号： A61K31/438 ,  A61K31/501 ,  A61K31/497 ,  A61K31/506 ,  C07D491/147 ,  C07D471/10

    CPC分类号： C07D471/10

    摘要： Certain novel N-acylated spiropiperidine derivatives are ligands of the human melanocortin receptor(s) and, in particular, are selective ligands of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of MC-4R, such as obesity, diabetes, nicotine addiction, alcoholism, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.

    摘要翻译： 某些新型N-酰化螺哌啶衍生物是人类黑皮质素受体的配体，特别是人黑素皮质素-4受体（MC-4R）的选择性配体。 因此，它们可用于治疗，控制或预防对调节MC-4R的疾病和病症，例如肥胖，糖尿病，尼古丁成瘾，酒精中毒，性功能障碍，包括勃起功能障碍和女性性功能障碍。

    ANGIOTENSIN II RECEPTOR ANTAGONISTS
    55.
    发明申请
    ANGIOTENSIN II RECEPTOR ANTAGONISTS 失效
    ANGIOTENSIN II受体拮抗剂

    公开(公告)号：US20100144810A1

    公开(公告)日：2010-06-10

    申请号：US12629419

    申请日：2009-12-02

    申请人： Michael Man-Chu Lo ,  Amjad Ali ,  Ravi P. Nargund

    发明人： Michael Man-Chu Lo ,  Amjad Ali ,  Ravi P. Nargund

    IPC分类号： A61K31/4178 ,  C07D403/10 ,  C07D257/04 ,  C07D409/06 ,  A61K31/41 ,  A61K31/4184 ,  A61P9/12

    CPC分类号： C07D403/10 ,  C07D235/08 ,  C07D257/04 ,  C07D409/06

    摘要： A compound having the structure wherein R is an angiotensin receptor antagonist active group, and Y is Y is selected from the group consisting of R1 is selected from the group consisting of —O—C1-6 alkyl, —O-aryl, —O-heteroaryl, —O—C3-8 cycloalkyl, —C1-6 alkyl, -aryl, -heteroaryl, and —C3-8 cycloalkyl; R2 and R3 are independently selected from the group consisting of hydrogen and C1-4 alkyl, or a pharmaceutically acceptable salt or hydrate thereof, which is useful for treating hypertension.

    摘要翻译： 具有其中R为血管紧张素受体拮抗剂活性基团且Y为Y的结构的化合物选自R 1选自-O-C 1-6烷基，-O-芳基，-O- 杂芳基，-O-C 3-8环烷基，-C 1-6烷基， - 芳基， - 杂芳基和-C 3-8环烷基; R2和R3独立地选自氢和C 1-4烷基，或其药学上可接受的盐或水合物，其可用于治疗高血压。

    Acylated piperidine derivatives as melanocortin 4-receptor agonists
    56.
    发明授权
    Acylated piperidine derivatives as melanocortin 4-receptor agonists 失效
    酰基化哌啶衍生物作为黑皮质素4-受体激动剂

    公开(公告)号：US07618987B2

    公开(公告)日：2009-11-17

    申请号：US11632000

    申请日：2005-07-15

    申请人： Raman K. Bakshi ,  James P. Dellureficio ,  Ravi P. Nargund

    发明人： Raman K. Bakshi ,  James P. Dellureficio ,  Ravi P. Nargund

    IPC分类号： C07D401/02 ,  A61K31/454

    CPC分类号： C07D401/06 ,  C07D211/62 ,  C07D401/14 ,  C07D413/14

    摘要： Certain novel N-acylated piperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.

    摘要翻译： 某些新的N-酰化哌啶衍生物是人类黑皮质素受体的激动剂，特别是人黑皮质素-4受体（MC-4R）的选择性激动剂。 因此，它们可用于治疗，控制或预防对MC-4R的激活反应的疾病和病症，例如肥胖，糖尿病，性功能障碍，包括勃起功能障碍和女性性功能障碍。

    Spiropiperidine derivatives as melanocortin receptor agonists
    57.
    发明授权
    Spiropiperidine derivatives as melanocortin receptor agonists 失效
    螺哌啶衍生物作为黑皮质素受体激动剂

    公开(公告)号：US06472398B1

    公开(公告)日：2002-10-29

    申请号：US09812339

    申请日：2001-03-20

    申请人： Brenda L. Palucki ,  Ravi P. Nargund

    发明人： Brenda L. Palucki ,  Ravi P. Nargund

    IPC分类号： A61K31496

    CPC分类号： C07D471/10 ,  A61K38/00 ,  C07K5/06139

    摘要： Certain novel spiropiperidine derivatives of structural formula Ia wherein the substituents are as defined herein are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.

    摘要翻译： 某些结构式Ia的新型螺哌啶衍生物，其中取代基如本文所定义，是人黑皮质素受体的激动剂，特别是人黑皮质素-4受体（MC-4R）的选择性激动剂。 因此，它们可用于治疗，控制或预防对MC-4R的激活反应的疾病和病症，例如肥胖，糖尿病，性功能障碍，包括勃起功能障碍和女性性功能障碍。